Biotest AG: Biotests Pentaglobin(R) is a treatment option for COVID-19 patients additionally affected by bacterial infections
DGAP-News: Biotest AG
/ Key word(s): Research Update
Biotests Pentaglobin(R) is a treatment option for COVID-19 patients additionally affected by bacterial infections
- Secondary bacterial infections increasingly observed when the clinical progression of COVID-19 is severe
- Pentaglobin(R) supports the immune system in eliminating bacteria and toxins
- Pentaglobin(R) regulates excessive immune responses
- Aiming for alleviating of overcrowded intensive care units
Dreieich, 26 November 2020. Pentaglobin(R) is the only immunoglobulin M (IgM)-enriched preparation on the global market. It is approved for the treatment of severe bacterial infections with concomitant use of antibiotics. Secondary bacterial infections are increasingly being observed in COVID-19 patients when the clinical progression of the disease is severe. The antibodies in Pentaglobin(R) can bind to many different bacteria and their toxins, assisting in their destruction by the immune system. Also, the IgM content in Pentaglobin(R) supports the immune system and is able to restore the balance of the immune response which is often excessive in COVID-19 patients.
With Pentaglobin(R) Biotest is offering an established treatment option for bacterial infections which can also be used to treat severely ill COVID-19 patients. Pentaglobin(R) was able to significantly reduce mortality in patients with sepsis and shorten the length of mechanical ventilation. It is therefore conceivable that treatment with Pentaglobin(R) may also reduce the length of and need for mechanical ventilation in COVID-19 patients. This could result in a reduction in the length of stay in intensive care units and ease the strain on limited capacity. First case reports on the use of Pentaglobin(R) in COVID-19 patients show promising results.
In addition to this, with trimodulin Biotest is developing a polyvalent antibody preparation to combat COVID-19, as well as a COVID-19 hyper immunoglobulin as part of a plasma alliance cooperation. Biotest is therefore pursuing a number of promising approaches aimed at providing critically ill COVID-19 patients with further effective treatment options as quickly as possible by means of accelerated approval procedures.
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
26.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Phone:||0 61 03 - 8 01-0|
|Fax:||0 61 03 - 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1150631|
|End of News||DGAP News Service|